Current Report Filing (8-k)
May 17 2018 - 6:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
May 16, 2018
STELLAR BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified
in its charter)
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
332 E. Scott Street
Port Hueneme, California 93041
(Address of principal executive offices)
(Zip Code)
(805) 488-2800
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
þ
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
þ
Stellar Biotechnologies, Inc. (the “Company”)
reports that on May 16, 2018, it had 3,196,266 common shares issued and outstanding. This includes 305,000 shares that the Company
issued pursuant to the exercise of pre-funded warrants issued in the Company’s best efforts public offering of units and
pre-funded units, as previously disclosed in a Current Report on Form 8-K filed with the SEC on May 15, 2018.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Stellar
Biotechnologies, Inc.
|
|
|
|
|
Date: May 17, 2018
|
By:
|
/s/ Kathi Niffenegger
|
|
|
Name:
|
Kathi Niffenegger
|
|
|
Title:
|
Chief Financial Officer
|
|
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Jul 2023 to Jul 2024